Recombinant Moraxella bovoculi cytotoxin-ISCOM matrix adjuvanted vaccine to prevent naturally occurring infectious bovine keratoconjunctivitis.
A randomized, blinded, controlled field trial was conducted during summer 2006 in a northern California, USA, herd of beef cattle to evaluate the efficacy of a recombinant Moraxella bovoculi cytotoxin subunit vaccine to prevent naturally occurring infectious bovine keratoconjunctivitis (IBK; pinkeye). A convenience sample comprised of 127 steers were administered a subcutaneous dose of either adjuvant alone (ISCOM matrices; control group) or recombinant M. bovoculi cytotoxin carboxy terminus adjuvanted with ISCOM matrices (MbvA group) and were boostered 21 days later. The steers were examined once weekly for 15 weeks for evidence of IBK. No significant difference in the cumulative proportion of corneal ulcerations was detected between groups. Compared to the control calves, the MbvA vaccinates had significantly higher increases in serum neutralizing titers to M. bovoculi hemolysin between week 0 and week 6. The prevalence of M. bovis isolations was higher from ulcerated eyes of calves vaccinated with MbvA as compared to control calves. Vaccination of calves against the carboxy terminus of M. bovoculi RTX toxin resulted in significant increases in serum hemolysin neutralizing titers and may modulate organism type cultured from ulcerated eyes of calves in herds where both M. bovis and M. bovoculi exist. Use of M. bovoculi antigens alone in vaccines to prevent IBK may not be beneficial in herds where IBK is associated with both M. bovoculi and M. bovis.
Angelos
John A
JA
Department of Medicine and Epidemiology, University of California, Davis, CA 95616, USA. jaangelos@ucdavis.edu
Lane
V Michael
VM
Ball
Louise M
LM
Hess
John F
JF
D000276:Adjuvants, Immunologic; D000818:Animals; D001427:Bacterial Toxins / Q000276:immunology; D001428:Bacterial Vaccines / Q000276:immunology*; D002417:Cattle; D003603:Cytotoxins / Q000737:chemistry / Q000276:immunology*; D016882:ISCOMs / Q000737:chemistry / Q000276:immunology*; D007639:Keratoconjunctivitis, Infectious / Q000517:prevention & control*; D009016:Moraxella / Q000145:classification*; D045828:Moraxellaceae Infections / Q000517:prevention & control / Q000662:veterinary*; D014614:Vaccines, Synthetic / Q000276:immunology
D000276:Adjuvants, Immunologic; D001427:Bacterial Toxins; D001428:Bacterial Vaccines; D003603:Cytotoxins; D016882:ISCOMs; D014614:Vaccines, Synthetic